Cargando…

Re-engineering anti-CTLA-4 antibodies for enhancing cancer immunotherapy efficacy and safety

Detalles Bibliográficos
Autor principal:	Seeruttun, Sharvesh Raj
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AIMS Press 2019
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6803786/ https://www.ncbi.nlm.nih.gov/pubmed/31663034 http://dx.doi.org/10.3934/genet.2019.3.64

Ejemplares similares

Equibalancing immune‐related adverse events and anticancer activity of immune checkpoint inhibitors
por: Seeruttun, Sharvesh Raj
Publicado: (2019)

New tricks for old targets: Anti-CTLA-4 antibodies re-envisioned for cancer immunotherapy
por: Waight, Jeremy D., et al.
Publicado: (2018)

Maximum Somatic Allele Frequency in Combination With Blood-Based Tumor Mutational Burden to Predict the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer: A Pooled Analysis of the Randomized POPLAR and OAK Studies
por: Chen, Yu-tong, et al.
Publicado: (2019)

Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice
por: Du, Xuexiang, et al.
Publicado: (2018)

Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy
por: Fan, Xiaozhou, et al.
Publicado: (2014)

An anti-CTLA-4 heavy chain–only antibody with enhanced T(reg) depletion shows excellent preclinical efficacy and safety profile
por: Gan, Xin, et al.
Publicado: (2022)

Fc-independent functions of anti-CTLA-4 antibodies contribute to anti-tumor efficacy
por: Sato, Yosuke, et al.
Publicado: (2022)

Anti-CTLA-4 antibodies in cancer immunotherapy: selective depletion of intratumoral regulatory T cells or checkpoint blockade?
por: Tang, Fei, et al.
Publicado: (2018)

TIL therapy and anti-CTLA4: can they co-exist?
por: Forget, Marie-Andrée, et al.
Publicado: (2019)

A Novel Mice Model for Studying the Efficacy and IRAEs of Anti-CTLA4 Targeted Immunotherapy
por: Xu, Shengchao, et al.
Publicado: (2021)

Bispecific antibodies targeting CTLA-4: game-changer troopers in cancer immunotherapy
por: Farhangnia, Pooya, et al.
Publicado: (2023)

CTLA-4 in Regulatory T Cells for Cancer Immunotherapy
por: Sobhani, Navid, et al.
Publicado: (2021)

Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV(+) oral cancer
por: Dorta-Estremera, Stephanie, et al.
Publicado: (2019)

Special Issue “Antibody Engineering for Cancer Immunotherapy”
por: Crescioli, Silvia, et al.
Publicado: (2022)

Clinical significance and diagnostic value of serum CEA, CA19-9 and CA72-4 in patients with gastric cancer
por: Liang, Yao, et al.
Publicado: (2016)

A New Strategy Using ALDH(high)-CD8+T Cells to Inhibit Tumorigenesis
por: Luo, Huiyan, et al.
Publicado: (2014)

Engineering a Smart Agent for Enhanced Immunotherapy Effect by Simultaneously Blocking PD‐L1 and CTLA‐4
por: Jiang, Chunjuan, et al.
Publicado: (2021)

Neoantigen cancer vaccine augments anti-CTLA-4 efficacy
por: Salvatori, Erika, et al.
Publicado: (2022)

Preparative immunotherapy with anti-OX40 and anti-CTLA4 improves the response to chemotherapy
por: Friedman, David J, et al.
Publicado: (2014)

Correction for Gan et al., An anti-CTLA-4 heavy chain–only antibody with enhanced T(reg) depletion shows excellent preclinical efficacy and safety profile
Publicado: (2022)

Correction for Gan et al., An anti-CTLA-4 heavy chain–only antibody with enhanced T(reg) depletion shows excellent preclinical efficacy and safety profile
Publicado: (2023)

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies
por: Peggs, Karl S., et al.
Publicado: (2009)

Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy
por: Zhang, Yan, et al.
Publicado: (2019)

Prevalence of hypertension and prehypertension in Nepal: a systematic review and meta-analysis
por: Huang, Yun, et al.
Publicado: (2019)

Recurrence risk stratification based on Epstein–Barr virus DNA to identify enlarged retropharyngeal lymph nodes of nasopharyngeal carcinoma: A model-histopathologic correlation study
por: Mao, Minjie, et al.
Publicado: (2022)

CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab)
por: Fietz, Simon, et al.
Publicado: (2020)

Anti–CTLA-4 therapy requires an Fc domain for efficacy
por: Ingram, Jessica R., et al.
Publicado: (2018)

Patients with chronic lymphocytic leukaemia (CLL) differ in the pattern of CTLA-4 expression on CLL cells: the possible implications for immunotherapy with CTLA-4 blocking antibody
por: Ciszak, Lidia, et al.
Publicado: (2015)

Recurrent SERPINB3 and SERPINB4 Mutations in Patients that Respond to Anti-CTLA4 Immunotherapy
por: Riaz, Nadeem, et al.
Publicado: (2016)

A homogenized approach to classify advanced gastric cancer patients with limited and adequate number of pathologically examined lymph nodes
por: Seeruttun, Sharvesh Raj, et al.
Publicado: (2019)

Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application
por: Ascierto, Paolo A, et al.
Publicado: (2011)

Adverse Events Following Administration of Anti-CTLA4 Antibody Ipilimumab
por: Karimi, Amirali, et al.
Publicado: (2021)

Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials
por: Hao, Chunyan, et al.
Publicado: (2017)

A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
por: Du, Xuexiang, et al.
Publicado: (2018)

CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations
por: Camacho, Luis H
Publicado: (2015)

Thermosensitive hydrogel releasing nitric oxide donor and anti-CTLA-4 micelles for anti-tumor immunotherapy
por: Kim, Jihoon, et al.
Publicado: (2022)

Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion
por: Ribas, Antoni, et al.
Publicado: (2012)

New emerging targets in cancer immunotherapy beyond CTLA-4, PD-1 and PD-L1: Introducing an “ESMO Open – Cancer Horizons” Series
por: Lambertini, Matteo, et al.
Publicado: (2019)

Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
por: Seidel, Judith A., et al.
Publicado: (2018)

Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
por: Arce Vargas, Frederick, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ehre9vvqfgdp3hbg3uvmki8q5q